Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.74 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.60 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 2/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21769114 | 0.86 | CRBN (0.76) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL283113 | 0.85 | CRBN (0.74) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL21751110 | 0.85 | CRBN (1.00) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL4778581 | 0.84 | CRBN (0.73) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL26646479 | 0.83 | CRBN (0.77) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL28814069 | 0.83 | CRBN (0.70) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL4781353 | 0.83 | CRBN (0.77) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL21751086 | 0.81 | CRBN (0.69) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL4780718 | 0.81 | CRBN (0.61) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL20811955 | 0.80 | CRBN (0.72) | CRBNDDB1IKZF3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110621664-B | Novel piperidine-2, 6-dione derivatives and uses thereof | 韩国化学研究院 | 2023-08-01 | — | — | CN | disclosed |
| EP-3623366-B9 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2022-06-15 | — | — | EP | disclosed |
| EP-3623366-B1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2022-01-19 | — | — | EP | disclosed |
| US-11192878-B2 | Piperidine-2,6-dione derivative and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-12-07 | — | — | US | disclosed |
| US-11192878-B2 | Piperidine-2,6-dione derivative and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-12-07 | — | — | US | disclosed |
| EP-3623366-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2020-03-18 | — | — | EP | disclosed |
| US-20200062730-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2020-02-27 | — | — | US | disclosed |
| US-20200062730-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2020-02-27 | — | — | US | disclosed |
| CN-110621664-A | Novel piperidine-2, 6-dione derivatives and uses thereof | 韩国化学研究院 | 2019-12-27 | — | — | CN | disclosed |
| US-20170369471-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2017-12-28 | — | — | US | disclosed |
| EP-2066656-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORP (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2428513-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | Celgene Corporation (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2420497-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORPORATION (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420498-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | Celgene Corporation (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION. | 2010-04-15 | — | — | US | disclosed |
| US-7635700-B2 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| CN-101535291-A | 5-substituted quinazolinone derivatives as antitumor agents | CELGENE CORP (US) | 2009-09-16 | — | — | CN | disclosed |
| EP-2066656-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION | 2008-07-03 | — | — | US | disclosed |
| WO-2008039489-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | FGF2, TNF, FGF1 | CRBN 2562/4885DDB1 2526/4885IKZF3 3719/4885 |
| US-20200062730-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | CRBN, PDCD11, CD47 | CRBN 1/4885DDB1 153/4885IKZF3 969/4885 |
| US-11192878-B2 | Piperidine-2,6-dione derivative and use thereof | CRBN, PDCD11, CD47 | CRBN 1/4885DDB1 196/4885IKZF3 822/4885 |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | CRBN 3139/4885DDB1 4060/4885IKZF3 4145/4885 |
| US-20170369471-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | CRBN 3139/4885DDB1 4060/4885IKZF3 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.